ArticleVirology journal2025
Epidemiology of hepatitis delta virus (HDV) infection and comparison of clinical characteristics and disease progression among patients with HDV vs. hepatitis B mono-infection: real-world data from a large healthcare insurer-provider in Israel.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recommendations for treatment of viral hepatitis B in 2026 by the Polish Group of Experts for HBV.Clinical and experimental hepatology · 2026Review
- Association between chronic hepatitis B virus infection and stroke risk: a propensity score-matched analysis.Epidemiology and infection · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis delta virus (HDV) infection occurs in patients with underlying hepatitis B virus (HBV) infection and is associated with more rapid liver disease progression. This study aimed to describe the epidemiology of HDV, describe HDV management, and compare disease progression among patients with HDV vs. HBV mono-infection in Israel.
methodsThis retrospective cohort study used anonymized data from Maccabi Healthcare Services. HDV prevalence and incidence were calculated among adults in 2010-2021 (latest decade, PCR test available in the database). HDV management and progression to a more advanced disease state and/or death (composite outcome) were examined in 2005-2021 (maximize follow up, antibody test available in the database). Disease progression post-index compared among HDV (index = earliest diagnosis or HDV-positive laboratory test) vs. HBV mono-infection (index = earliest HDV-negative test) by baseline disease state using Kaplan-Meier and Cox analysis.
resultsFrom 2010 to 2021, average annual HDV prevalence and incidence rates among patients with HBV (general population) were 2.3% (12.4/100,000) and 0.11% (0.59/100,000), respectively. From 2005 to 2021, patients with HDV (N = 168) vs. HBV mono-infection (N = 2,580) had lower socioeconomic status and higher baseline prevalence rates for HIV, HCV PCR positive, diagnosed drug dependence, and alcohol abuse. Risk of disease progression was higher among patients with HDV vs. HBV mono-infection (adjusted HR = 4.4, P < 0.001).
conclusionsHDV prevalence among adults with HBV remained steady. Patients with HDV vs. HBV mono-infection had higher risk of progression to a more advanced liver disease state and/or death. The results of this study underscore a need for earlier identification of HDV infection, as well as more effective strategies for the diagnosis and treatment of HDV to mitigate future disease progression.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.